Souhaitez-vous accéder aux communiqués récents ?

BOTHELL, Wash., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that James Martin, CFO and co-CEO, will present a Company overview...

Global Virus Network issued a statement on the emergence of a new influenza A (H3N2) variant known as H3N2 subclade K that is spreading rapidly.

In-Vitro Data Confirms Strong Protection Against H1N1 Influenza via Physical Barrier Mechanism Ra’anana, Israel, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the...

Phase 2b to assess efficacy, safety, and immunogenicity2,850 participants to be enrolled across European countries  Lyon, France and Liège, Belgium – September 16, 2025 – Osivax, a biopharmaceutical...

Funding to accelerate development of Osivax’ broad-spectrum influenza A vaccine candidate, OVX836  Lyon, France and Liège, Belgium – August 26, 2025 – Osivax, a biopharmaceutical company developing...

Co-administration of OVX836 with seasonal inactivated influenza vaccine (Fluarix® Tetra) was well-tolerated and demonstrated a favorable safety profileRobust complementary immune responses were...

Pneumagen’s intranasal broad-spectrum antiviral therapy reduced infection, improved symptoms and severity and reduced viral load in a Phase II influenza study in data published in the high-impact,...

OCALA, Fla., June 11, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (OTC Pink: AIMID) (NYSE American: AIM) (“AIM” or the “Company”) today announced a reverse stock split (“Reverse Stock Split”) of...

Final results expected in H2 2025 Lyon, France – June 5, 2025 – Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating respiratory...

PDSB announced that Infectimune® immune response data were featured at the American Association of Immunologists’ IMMUNOLOGY2025™ Annual Meeting.